PHGE

BiomX is a pre-revenue, clinical-stage phage company in active financial collapse, not a speculative call with an asymmetric payoff. The 10-K carries an explicit going-concern paragraph: management states cash of $5.0M (XBRL cash & equivalents $4.36M, down 74.1% YoY) funds operations only through the end of Q2 2026 — i.e., roughly now, as of this July 2026 read. In December 2025 the Israeli operating subsidiary, BiomX Ltd., commenced insolvency proceedings, and the company discontinued its lead candidate BX004 after the DMC flagged adverse events, then cut its workforce. When a clinical-stage company kills its lead program and puts its main operating entity into insolvency, the value engine is gone; what remains is a shell exploring 'strategic alternatives.'

The balance sheet confirms the distress: stockholders' equity is negative at -$1.30M (down 105.4% YoY), current liabilities ($6.38M) exceed current assets ($5.58M), total assets collapsed 86.6% to $5.78M, and the accumulated deficit sits at -$217M against ~$217.3M of lifetime securities proceeds raised — the company has consumed essentially every dollar it ever raised. FY2025 net loss widened to -$36.2M (from -$17.7M) and operating cash flow was -$26.4M, so against ~$4.4M of cash the runway is measured in weeks, not quarters. There is no revenue in any year shown (FY2021–FY2025), so no fundamental floor.